Treace Medical Beats Q2, Expands Bunion System Portfolio

Treace Medical Concepts reported Q2 2025 revenue of $47.4 million, a 7% increase year-over-year that exceeded analyst expectations. The company narrowed its net loss to $(0.28) per share, highlighting improved operational efficiency and cost control. Gross profit rose to $37.8 million, with a robust gross margin of 79.7%. Treace executed a full market release of new bunion correction systems and published four-year clinical data supporting its Lapiplasty system. Despite these achievements, shares have declined about 26.5% year-to-date amid broader market challenges. The company reaffirmed its FY2025 sales guidance and is investing in surgeon training and patient outreach to support further adoption.